New drug trial aims to protect young brains from sickle cell damage
NCT ID NCT05725902
Summary
This small, early-stage study is testing whether a drug called etavopivat can improve blood flow and oxygen delivery to the brain in children and young adults with sickle cell disease. Researchers will use special light-based scanners to measure brain blood flow in about 12 participants before, during, and after 24 weeks of taking the drug. The main goal is to see if the drug helps the brain get more oxygen, which could help prevent long-term complications like stroke.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Children's Healthcare of Atlanta
Atlanta, Georgia, 30342, United States
Conditions
Explore the condition pages connected to this study.